

## **Sponsors**

---

**University of Minnesota**

College of Veterinary Medicine

College of Agricultural, Food and Environmental Sciences

Extension Service

Swine Center

# **Immunomodulation. Therapy of the Future in the Porcine Health**

Ferro A., Marca J., Tarés J..

R & D department, Laboratorios Calier S.A. Les Franqueses del Vallès, Catalunya.  
Spain

**Introduction** The raising presence of infectious immunosuppressing agents, which cause primary and secondary processes, interferes with the capacity of response of the animals, favouring the appearance of secondary pathologies hard to solve. The current porcine production, management and housing systems drive to frequent situations of stress, with a known immunosuppressing effect. All this leads to situations that require to be analyzed with an approach that guarantees as much as possible the immune response of the pig. Thus it can be stated that a vaccine or an antiinfectious disables the pathogen's functionality or integrity inside the individual, and an immunomodulator restores the physiological capacity of recuperation of that individual.

**Preceding** Some Research centers started their studies with immunomodulators: inactivated cells of the genus *Propionibacterium* and Lipopolysaccharides coming from the wall of a non-pathogen strain of *Escherichia coli* and some inactivated virus (1,2,3,4,11).

**LPS:** Lipopolysaccharide of the cellular wall of the G-. One of the main factors of antigenicity. Consists of a nucleus, common to all the LPS, and a radical (lateral chains). These lateral chains differentiate among the LPS. LPS of the INMODULEN\* (IMD) has a short chain and comes from an apathogen strain of *E. Coli*. In the blood it is linked to a LBP (Lipopolisaccharide binding protein).

**Effects LPS. 1<sup>st</sup> way of action:** Similar to the whole LPS. Due to the universality of the molecule, superior organisms have developed response mechanisms against LPS in the whole cells of the immune system. These cells contain a specific receiver for the LPS: CD14. When activated, sets off the immune response. It is the substance with the highest capacity to

activate macrophages. **2<sup>nd</sup> way of action:** Lymphocytes B. It is a T-independent antigen.

## **Propionibacterium spp**

**Way of action:** Macrophages: captivated, degraded and presented in the membrane to lymphocytes T. IMD, with no cynetic pharmacology, does not present time of effect since it sets off a non-specific immune response's process that lasts so much depending on the individual.

## **INMODULEN® CLINICAL EXPERIENCE.**

We have appraised benefits with the application of the product in such varied fields as: Replacement sows – Adaptation to the new environment, Reproductive disorders, Ig-A increases in milk, Resistance to illness, Increase of the capacity of response against PRDC, Compatible, in vivo and in vitro, with Aujeszky and PRRS vaccination programs and enhance the immune homogeneity of the farm: Subpopulations. (5, 6, 7, 8, 9, 10).

\* Parenteral suspension containing LPS from non pathogenic *E coli* and inactivated cells from *Propionibacterium spp*.

## **References**

1. McGhee et al. Lipopolysaccharide regulation of the IgA immune response. Recent advances in mucosal immunity. Raven Press. NY 1982.
2. D.M. Jacobs. Lipopolysaccharide and the immune response. Recent advances in mucosal immunology. Raven Press. NY 1982.
3. Alvarez et al. Analysis of the in vitro effects of compound IM-104 on several parameters of the pig immune response. J. Vet. Pharmacol. Therap. 20 (supl. 1). 127-180. 1997 Blackwell Science Ltd.

4. Alvarez et al. Efecto in vitro del compuesto IM-104 sobre determinados parámetros inmunológicos. XVII Symposium Anaporc. Santiago de Compostela (España) 1996.
5. Stipkovits et al. Efecto comparativo de Inmodulen frente a la antibioterapia convencional en la neumonía bacteriana porcina. 15<sup>th</sup> IPVS Congress. Birmingham (UK) 1998.
6. Marca et al. Efficacy of Inmodulen in pigs naturally infected with M. Hyopneumoniae. 14<sup>th</sup> IPVS Congress. Bologna (Italy) 1996.
7. Ortiz, J. M. et al. Niveles de Ig A en el calostro de cerdas tratadas con Inmodulen®. Proyecto Eureka EU 1183 "EUROAGRI INMODULEN (DEF). XVII Symposium Anaporc. Santiago de Compostela (España) 1996.
8. Rierola, J. (Consultor de porcino), Tarés, J., Marca, J. (Departamento Marca et al. de I + D. Laboratorios Calier, S.A.). Inmunomodulación en cerdas reproductoras. Aumento de la viabilidad neonatal y reducción de la incidencia de procesos entéricos en lactación. XVIII Symposium Anaporc. Lleida (España) 1997.
9. Casal, J., Mateu, E. et al. Respuesta inmune "in vitro" e "in vivo" a la administración de IM – 104 en cerdos. Efecto frente al virus de la enfermedad de Aujeszky. Universidad Autónoma de Barcelona (España) 1998. Non published data.
10. Dominguez, J. et al. Análisis del efecto "in vivo" del INMODULEN sobre la respuesta inmune del cerdo al virus del PRRS. Centro de Investigación en Sanidad Animal (INIA), Valdeolmos, Madrid, (España) 1998. Non published data.
11. Mayr, A. "Nutzung der Paramunisierung in der Schweinehaltung". Tierärztl. Praxis **14**, 237-244 (1986).